This real world study reports on the long term survival of patients with metastatic renal cell carcinoma (RCC) who have taken 1 to 4 lines of systemic drug treatment sequentially under real life conditions.

Patients were treated according to their prognostic score (good, intermediate, poor). Overall survival was 57 months in patients with good or intermediate prognosis and 19 months in patients with poor prognosis.

The results from this real world study reflect the changes in the treatment landscape for metastatic RCC over the last decade through the development of anti-angiogenic agents, mTOR inhibitors, and immunotherapy.

Read more in UroToday here